[go: up one dir, main page]

WO2000033815A1 - Preparations poudreuses en aerosol contenant un fongicide - Google Patents

Preparations poudreuses en aerosol contenant un fongicide Download PDF

Info

Publication number
WO2000033815A1
WO2000033815A1 PCT/JP1999/006852 JP9906852W WO0033815A1 WO 2000033815 A1 WO2000033815 A1 WO 2000033815A1 JP 9906852 W JP9906852 W JP 9906852W WO 0033815 A1 WO0033815 A1 WO 0033815A1
Authority
WO
WIPO (PCT)
Prior art keywords
antifungal agent
aerosol
powder
nitrate
fungicide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1999/006852
Other languages
English (en)
Japanese (ja)
Inventor
Tsuyoshi Uchiyama
Ariko Imaoji
Megumi Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Priority to AU14159/00A priority Critical patent/AU1415900A/en
Publication of WO2000033815A1 publication Critical patent/WO2000033815A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids

Definitions

  • the present invention relates to an aerosol formulation containing an antifungal agent, and more particularly, to an aerosol formulation containing an antifungal agent containing a powder component for the purpose of drying an affected part and promoting healing. It is about.
  • Fungal infections on the skin include tinea, candidiasis, and starchy dermatitis.Dry skin symptoms include erythema and desquamation, and wet forms with erythema, vesicles, maceration, and erosion There is. Antifungal agents are used in these treatments, and many formulations have been developed, including ointments, creams, solutions, and aerosols. Under these circumstances, powdered aerosol formulations containing antifungal agents and powdered components have been developed with the aim of drying wet moistened affected areas to speed treatment and prevent secondary infection. JP-A-5-246643 discloses a dry spray type antifungal-containing composition. Japanese Patent Application Laid-Open No. 8-129964 discloses a powder aerosol containing an antifungal agent which is difficult to fall off the skin.
  • azolic drugs such as miconazole nitrate, econazole nitrate, and oxyconazole nitrate, which have an antibacterial spectrum against not only ringworm but also Candida, have been awarded for fungal infections. Have been used. However, these drugs have extremely low solubility of base components generally used in external preparations in solvents such as water and alcohol. For this reason, Japanese Patent Application Laid-Open No. 4-173733 describes an antifungal external preparation prepared by dissolving an antifungal agent in an external base using amines such as diphenhydramine, lidocaine, and diethanolamine. Is disclosed.
  • this technology dissolves an antifungal agent in a large amount of an external base, and requires a quick drying property such as a powder aerosol formulation.
  • Antifungals present in aerosol formulations in crystalline form are sprayed in crystalline form, so their absorption and penetration into the stratum corneum are low and the actual therapeutic effect is not sufficient.
  • the antifungal agent is settled at the bottom of the aerosol can in a crystalline state, if the shaking before use is insufficient, the antifungal agent in the aerosol can is not evenly dispersed and The concentration cannot be applied, and a sufficient therapeutic effect cannot be expected.
  • the present invention provides an antifungal agent-containing powder aerosol formulation in which an antifungal agent is present in a dissolved state in a powder aerosol formulation in which only a small amount of a dissolved component is required because quick drying is required. Disclosure of the invention
  • the present inventors have conducted intensive studies in order to solve the above-mentioned problems. As a result, the combination of a lower alcohol with at least one of isopropanolamines and amylamines in a fungal preparation, The present inventors have found that the antifungal agent can be uniformly present in the aerosol formulation in a dissolved state even when the propellant is filled by setting the predetermined amount, and the present invention has been completed.
  • the present invention is a powdered aerosol formulation containing an antifungal agent, which comprises an antifungal agent, a lower alcohol, at least one of isopropanolamines and amylamines, and a propellant.
  • an azole antifungal agent which is known to be hardly soluble is preferably used.
  • azo-based antifungal agents particularly preferred are methanolic nitrate, econazole nitrate, oxyconazole nitrate, sulconazole nitrate, ketoconazole, ratconazole, and itraconazole, which are hardly soluble in ethanol.
  • the compounding amount of the antifungal agent is 0.03% to 5% by mass based on the total amount of the preparation. These are determined by considering the efficacy and safety of the drug.
  • the lower alcohol is effective as a component of a liquid base used for improving the adhesion of the powder to the skin at the time of injection and dissolving the active ingredient.
  • the lower alcohol is a monohydric alcohol having 1 to 3 carbon atoms, and examples thereof include methanol, ethanol, isopropanol, and denatured ethanol. Particularly, ethanol and isopropanol are preferred.
  • These components dissolve the antifungal agent It has a relatively low boiling point and is effective as a quick-drying liquid base that is characteristic of powdered aerosols.
  • the compounding amount is 1 to 20% by mass, preferably 3 to 15% by mass based on the total amount of the preparation. If the amount is less than 1%, the dissolution of the antifungal agent cannot be assisted, and if it is more than 20%, the quick-drying property as a powdery aerosol containing the antifungal agent cannot be realized.
  • isopropanolamines and amylamines are a component that helps the solubility of the antifungal agent.
  • Other amines cannot achieve the purpose of the present invention.
  • isopropanolamines include monoisopropanolamine, diisopropanolamine, and triisopropanolamine.
  • amylamines include normal amylamine, isoamylamine, neoamylamine and the like.
  • the content of these substances is 0.001 to 5% by mass based on the total amount of the preparation. Preferably it is 0.01 to 3% by mass. If the content is less than 0.001% by mass, it is difficult to achieve the above object, and if the content is more than 5% by mass, safety to the skin is concerned.
  • the powder component added to make a powder aerosol enhances the adhesion of the active ingredient to the skin, improves the dryness of wet parts, improves slipperiness and lubricity, and enhances usability. It is added for the purpose of dissolving or considering the suitability for the production of powder aerosols.
  • inorganic powders such as gay anhydride, magnesium silicate, talc, kaolin, aerosil, mica, zinc oxide, titanium oxide, magnesium oxide, magnesium carbonate, calamine, magnesium aluminate metasilicate
  • organic powders such as corn starch, potato starch, nylon powder, polyethylene powder, polystyrene powder, and cellulose powder. These powder components are used alone or in combination of two or more.
  • the compounding amount of the powder component is 0.5 to 15% by mass, preferably 2 to 10% by mass based on the total amount of the preparation. If the amount is less than 0.5% by mass, it is difficult to satisfy the above-mentioned object, and if the amount is more than 15% by mass, injection clogging with powder occurs, which is not preferable.
  • a liquefied gas is used as the propellant. Among them, fossil oil gas is preferable, and dimethyl ether may be added.
  • the amount of the propellant is 65 to 98% by mass, preferably 75 to 95% by mass, based on the total amount of the preparation.
  • the liquefied petroleum gas here includes not only ordinary propane, isobutane and normal butane but also a combination of components such as normal pentane, isopentane and neopentane.
  • the antifungal agent although not particularly limited, local anesthetics (such as lidocaine and aminoethyl benzoate), anti-inflammatory agents (such as allantoin and zinc oxide), and disinfectants (such as chloride Decalinium, benzalkonium chloride, etc.), anti-histamines (diphenhydramine, chlorpheniramine maleate, etc.), fresheners (1-menthol, d-1 camphor, etc.) can be added.
  • absorption of active ingredients improvement of permeability, improvement of skin safety, improvement of dispersion stability of powder in aerosol formulation, improvement of spreadability of powder and active ingredient at the time of injection, improvement of feeling of use, etc.
  • active ingredients improvement of permeability, improvement of skin safety, improvement of dispersion stability of powder in aerosol formulation, improvement of spreadability of powder and active ingredient at the time of injection, improvement of feeling of use, etc.
  • the following can be blended.
  • silicone oils such as methylpolysiloxane
  • hydrocarbons such as liquid paraffin and squalane
  • higher fatty acid esters such as isopropyl myristate, octyldodecyl myristate, and butyl stearate
  • vegetable oils such as olive oil and castor oil
  • Animal oils such as beeswax and squalene
  • nonionic surfactants such as sorbitan sesquioleate and polyglycerin fatty acid ester
  • Aerosols were manufactured according to the formulations shown in Tables 1 and 2 by a conventional method.
  • Dissolution The liquid content in the glass pressure bottle is one liquid, and the antifungal is dissolved. Undissolved: Antifungal agent has precipitated as crystals or oil at the bottom of the liquid content of the glass pressure bottle.
  • the aerosol of the example or comparative example shown in Table 3 was spray-coated on a silicone rubber film (2.5 cm x 5 cm) and stored in an environment of 35% humidity and 35% humidity. After a lapse of time, the concentration of miconazole nitrate in the silicone rubber film was measured, and the release of miconazole nitrate from the base material of the preparation was evaluated. The test was repeated three times, and the average was determined. The results are shown in Table 3.
  • Release rate% (silicon:! 'Concentration of miconazo nitrate in film'-film amount of silicon film 'conic acid miconazole nitrate'-amount) X 100 Test Example 3 [Evaluation of keratin retention]
  • the aerosol of the example or comparative example shown in Table 3 was spray-applied to the abdomen of a hairless rat, and after 6 hours, the application residue on the skin was wiped off with a rayon cloth soaked with an alcohol solution, and then applied to a transparent adhesive tape.
  • the stratum corneum of the applied part was peeled off, and the amount of miconazole nitrate contained therein was measured to determine the amount of drug stored in the stratum corneum. The test was repeated three times and the average was determined. Table 3 shows the results. Table 3
  • Example 6 the release of miconazole nitrate from the base material was high, and in experiments using rats, the amount of miconazole nitrate stored in the keratin, which is the location of the dermatomycosis fungi, was high and high. A therapeutic effect can be expected. As for the usability, it dried immediately after the spray application, giving a smooth feeling. In Comparative Example 9, since it is jetted in a crystalline state, the release from the base is low, the amount stored in the stratum corneum is small, and a sufficient therapeutic effect cannot be expected. Industrial applicability
  • the antifungal agent-containing powder aerosol formulation of the present invention allows the antifungal agent to be present in a dissolved state in the aerosol, so that the drug has a high permeability to the keratin and a consistently uniform drug injection. It can be applied, and it dries quickly and has a good feeling of use. Therefore, it is possible to provide a powder aerosol preparation which exhibits excellent therapeutic effects and a feeling of use for fungal skin diseases such as tinea, candily, and starch.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des préparations poudreuses en aérosol qui contiennent: (a) un fongicide; (b) un alcool de faible poids moléculaire; (c) au moins un élément choisi parmi les isopropanolamines et les amylamines; (d) un composant poudreux; et (e) un gaz de propulsion. Dans ces préparations, le fongicide peut se présenter sous forme dissoute en raison de la présence des amines spécifiques. On peut pulvériser ces préparations afin d'obtenir, de manière continue, une concentration uniforme de médicaments. Par ailleurs, ces préparations, qui présentent un remarquable pouvoir de pénétration dans la couche cornée de l'épiderme, peuvent sécher rapidement, ce qui a pour effet de stimuler leurs effets thérapeutiques en séchant les parties concernées.
PCT/JP1999/006852 1998-12-10 1999-12-07 Preparations poudreuses en aerosol contenant un fongicide Ceased WO2000033815A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU14159/00A AU1415900A (en) 1998-12-10 1999-12-07 Fungicide-containing powdery aerosol preparations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP10/351799 1998-12-10
JP35179998 1998-12-10

Publications (1)

Publication Number Publication Date
WO2000033815A1 true WO2000033815A1 (fr) 2000-06-15

Family

ID=18419694

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1999/006852 Ceased WO2000033815A1 (fr) 1998-12-10 1999-12-07 Preparations poudreuses en aerosol contenant un fongicide

Country Status (2)

Country Link
AU (1) AU1415900A (fr)
WO (1) WO2000033815A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014026213A1 (fr) * 2012-08-17 2014-02-20 Gebro Holding Gmbh Composition antiseptique

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6183117A (ja) * 1984-09-28 1986-04-26 Sumitomo Chem Co Ltd エアゾ−ル剤
JPS62273912A (ja) * 1986-05-21 1987-11-28 Kao Corp 人体塗布用エアゾ−ル剤
JPH04173734A (ja) * 1990-11-07 1992-06-22 Nitsusui Seiyaku Kk 抗真菌性外用剤
US5262150A (en) * 1990-09-26 1993-11-16 L'oreal Antifungus composition in dry spray form
JPH07242567A (ja) * 1994-03-04 1995-09-19 Showa Denko Kk 抗真菌外用剤
JPH0812964A (ja) * 1994-07-01 1996-01-16 Kobayashi Pharmaceut Co Ltd 粉末エアゾール組成物
JPH0840899A (ja) * 1994-07-29 1996-02-13 Tokyo Tanabe Co Ltd 硝酸オキシコナゾールのエアゾール剤

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6183117A (ja) * 1984-09-28 1986-04-26 Sumitomo Chem Co Ltd エアゾ−ル剤
JPS62273912A (ja) * 1986-05-21 1987-11-28 Kao Corp 人体塗布用エアゾ−ル剤
US5262150A (en) * 1990-09-26 1993-11-16 L'oreal Antifungus composition in dry spray form
JPH04173734A (ja) * 1990-11-07 1992-06-22 Nitsusui Seiyaku Kk 抗真菌性外用剤
JPH07242567A (ja) * 1994-03-04 1995-09-19 Showa Denko Kk 抗真菌外用剤
JPH0812964A (ja) * 1994-07-01 1996-01-16 Kobayashi Pharmaceut Co Ltd 粉末エアゾール組成物
JPH0840899A (ja) * 1994-07-29 1996-02-13 Tokyo Tanabe Co Ltd 硝酸オキシコナゾールのエアゾール剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014026213A1 (fr) * 2012-08-17 2014-02-20 Gebro Holding Gmbh Composition antiseptique

Also Published As

Publication number Publication date
AU1415900A (en) 2000-06-26

Similar Documents

Publication Publication Date Title
JP3268852B2 (ja) フエルビナクを含有する製剤学的組成物
CA2444533C (fr) Excipient pharmaceutique
WO2000023051A1 (fr) Compositions aerosol comprenant un onguent et leur procede de preparation
KR20070050040A (ko) 약제학적으로 우수한 국소용 무수 에어로졸 포움
WO2008038140A2 (fr) Vecteur expansible à base de polypropylène glycol et compositions pharmaceutiques associées
ES2391782T3 (es) Composición monofásica formadora de una película para la administación tópica
EP1959930A2 (fr) Compositions de fluidification et procede pour administrer par voie cutanee des medicaments
JP2013501780A (ja) 爪の真菌感染を治療するための組成物及び方法
JP2021515812A (ja) 抗真菌液剤およびフットワイプ
JPS6061518A (ja) ゲル状外用組成物
JP4438147B2 (ja) 抗真菌剤含有粉末エアゾール製剤
JP2009519956A (ja) 薬物の皮膚送達のための組成物および方法
JP2797401B2 (ja) 爪用抗真菌剤組成物
WO2000033815A1 (fr) Preparations poudreuses en aerosol contenant un fongicide
JP2001097848A (ja) 外用剤組成物
WO1994002126A1 (fr) Compositions et procedes pour le traitement topique des lesions de la peau
KR100288190B1 (ko) 피록시캄 함유 알콜성 하이드로겔 조성물
TW202239430A (zh) 外用劑組合物
JP5341397B2 (ja) エアゾール組成物
JP2001226258A (ja) 粉末エアゾール組成物
EP4563161A1 (fr) Composition pour préparation externe
KR100405920B1 (ko) 고분자 화합물을 포함하는 화장료 조성물
JPS63141918A (ja) かゆみ止め用エアゾ−ル組成物
JP2002167328A (ja) 皮膚外用組成物および皮膚外用エアゾール組成物

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 14159

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase